WO2002068476A3 - Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders - Google Patents

Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders Download PDF

Info

Publication number
WO2002068476A3
WO2002068476A3 PCT/US2002/005684 US0205684W WO02068476A3 WO 2002068476 A3 WO2002068476 A3 WO 2002068476A3 US 0205684 W US0205684 W US 0205684W WO 02068476 A3 WO02068476 A3 WO 02068476A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
inflammatory disorders
treating inflammatory
composition
antibodies
Prior art date
Application number
PCT/US2002/005684
Other languages
French (fr)
Other versions
WO2002068476A2 (en
Inventor
Kenneth Jacobs
Debra Pittman
Lynette Fouser
Vikki Spaulding
Dejun Xuan
Original Assignee
Inst Genetics Llc
Kenneth Jacobs
Debra Pittman
Lynette Fouser
Vikki Spaulding
Dejun Xuan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Genetics Llc, Kenneth Jacobs, Debra Pittman, Lynette Fouser, Vikki Spaulding, Dejun Xuan filed Critical Inst Genetics Llc
Priority to CA002438238A priority Critical patent/CA2438238A1/en
Priority to NZ527396A priority patent/NZ527396A/en
Priority to JP2002567986A priority patent/JP2005510451A/en
Priority to BR0207528-8A priority patent/BR0207528A/en
Priority to EP02721152A priority patent/EP1373319A2/en
Priority to AU2002252097A priority patent/AU2002252097A2/en
Priority to MXPA03007413A priority patent/MXPA03007413A/en
Publication of WO2002068476A2 publication Critical patent/WO2002068476A2/en
Priority to ZA2003/06071A priority patent/ZA200306071B/en
Publication of WO2002068476A3 publication Critical patent/WO2002068476A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.
PCT/US2002/005684 2001-02-23 2002-02-25 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders WO2002068476A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002438238A CA2438238A1 (en) 2001-02-23 2002-02-25 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
NZ527396A NZ527396A (en) 2001-02-23 2002-02-25 Antibodies and fragments thereof for the binding of IL-22 and use therefore for treating inflammatory disorders
JP2002567986A JP2005510451A (en) 2001-02-23 2002-02-25 Compositions and methods for treating inflammatory disorders
BR0207528-8A BR0207528A (en) 2001-02-23 2002-02-25 Antibody, pharmaceutical composition, and uses of an effective amount of an agent, a therapeutically effective amount of an il-22 antibody, an immunogenic amount of antigen, and an immunogenicity enhancing amount of il-22 in combination, a effective amount of the antibody or fragment thereof and a sufficient amount of antibody or antigen-linked fragment thereof
EP02721152A EP1373319A2 (en) 2001-02-23 2002-02-25 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
AU2002252097A AU2002252097A2 (en) 2001-02-23 2002-02-25 Composition and method for treating inflammatory disorders
MXPA03007413A MXPA03007413A (en) 2001-02-23 2002-02-25 Composition and method for treating inflammatory disorders.
ZA2003/06071A ZA200306071B (en) 2001-02-23 2003-08-06 Composition and method for treating inflammatory disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27082301P 2001-02-23 2001-02-23
US60/270,823 2001-02-23
US28135301P 2001-04-03 2001-04-03
US60/281,353 2001-04-03

Publications (2)

Publication Number Publication Date
WO2002068476A2 WO2002068476A2 (en) 2002-09-06
WO2002068476A3 true WO2002068476A3 (en) 2003-08-07

Family

ID=26954516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005684 WO2002068476A2 (en) 2001-02-23 2002-02-25 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders

Country Status (9)

Country Link
EP (1) EP1373319A2 (en)
JP (2) JP2005510451A (en)
AU (2) AU2002252097A2 (en)
BR (1) BR0207528A (en)
CA (1) CA2438238A1 (en)
MX (1) MXPA03007413A (en)
NZ (1) NZ527396A (en)
WO (1) WO2002068476A2 (en)
ZA (1) ZA200306071B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
JP5015404B2 (en) 2000-08-08 2012-08-29 ザイモジェネティクス， インコーポレイテッド Soluble ZCYTOR11 cytokine receptor
JP2005510451A (en) * 2001-02-23 2005-04-21 ジェネティクス インスティテュート，エルエルシー Compositions and methods for treating inflammatory disorders
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
US7265211B2 (en) 2002-03-22 2007-09-04 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of making
DK1606317T3 (en) 2003-03-24 2010-10-25 Zymogenetics Inc Anti-IL-22RA antibodies and binding partners as well as methods of use in inflammation
KR20060022289A (en) * 2003-06-23 2006-03-09 제네틱스 인스티튜트, 엘엘씨 Antibodies against interleukin-22 and uses therefor
CN101198625A (en) 2004-10-22 2008-06-11 津莫吉尼蒂克斯公司 Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
US20060177447A1 (en) 2005-02-08 2006-08-10 Wenfeng Xu Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP3006466B1 (en) * 2005-12-02 2018-08-01 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
TWI417301B (en) 2006-02-21 2013-12-01 Wyeth Corp Antibodies against human il-22 and uses therefor
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
CA3102391A1 (en) 2018-06-05 2019-12-12 Bioatla, Inc. Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2023110942A1 (en) * 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329274A1 (en) * 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
BR9914777A (en) * 1998-10-26 2001-07-03 Ludwig Inst Cancer Res Isolated nucleic acid molecules that encode factors inducible by t cells (tifs), encoded proteins and their uses
NZ515678A (en) * 1999-04-28 2004-01-30 Genetics Inst Human GIL-19/AE289 proteins and polynucleotides encoding same
EP1242600B1 (en) * 1999-12-23 2010-03-03 ZymoGenetics, Inc. Cytokine zcyto18
JP2005510451A (en) * 2001-02-23 2005-04-21 ジェネティクス インスティテュート，エルエルシー Compositions and methods for treating inflammatory disorders

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DUMOUTIER L ET AL: "CLONING AND CHARACTERIZATION OF IL-10-RELATED T CELL-DERIVED INDUCIBLE FACTOR (IL-TIF), A NOVEL CYTOKINE STRUCTURALLY RELATED TO IL-10 AND INDUCIBLE BY IL-9", JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, vol. 164, 2000, pages 1814 - 1819, XP000946156, ISSN: 0019-2805 *
DUMOUTIER L ET AL: "HUMAN INTERLEUKIN-10-RELATED T CELL-DERIVED INDUCIBLE FACTOR: MOLECULAR CLONING AND FUNCTIONAL CHARACTERIZATION AS AN HEPATOCYTE-STIMULATING FACTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 18, 29 August 2000 (2000-08-29), pages 10144 - 10149, XP000946025, ISSN: 0027-8424 *
DUMOUTIER L ET AL: "IL-TIF induces acute phase reactant production by hepatocytes through IL-10Rbeta.", IMMUNOLOGY LETTERS, vol. 73, no. 2-3, September 2000 (2000-09-01), 24th European Immunology Meeting of the European Federation of Immunological Societies;Poznan, Poland; September 23-26, 2000, pages 261, XP009012155, ISSN: 0165-2478 *
KOTENKO SERGEI V ET AL: "Identification of the functional interleukin-22 (IL-22) receptor complex. The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 4, 26 January 2001 (2001-01-26), pages 2725 - 2732, XP002186669, ISSN: 0021-9258 *
LAMBERT A ET AL: "Novel cytokine IL-22 administrated by adenovirus vector or as recombinant purified protein induces acute-phase responses and renal tubular basophilia in female C57BL/6 mice.", TOXICOLOGIC PATHOLOGY, vol. 29, no. 6, November 2001 (2001-11-01), Sixteenth Aspen Cancer Conference on Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention, and Cancer Therapy;Aspen, Colorado, USA; July 15-18, 2001, pages 712, XP009012154, ISSN: 0192-6233 *
XIE M-H ET AL: "Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 40, 6 October 2000 (2000-10-06), pages 31335 - 31339, XP002164307, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
JP2005510451A (en) 2005-04-21
AU2002252097A2 (en) 2002-09-12
JP2009137986A (en) 2009-06-25
BR0207528A (en) 2006-01-17
AU2008203342A1 (en) 2008-08-14
ZA200306071B (en) 2005-11-30
AU2008203342B2 (en) 2011-02-17
EP1373319A2 (en) 2004-01-02
AU2008203342B8 (en) 2011-03-17
CA2438238A1 (en) 2002-09-06
WO2002068476A2 (en) 2002-09-06
NZ527396A (en) 2007-12-21
MXPA03007413A (en) 2003-11-18

Similar Documents

Publication Publication Date Title
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
AU2003225800A1 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002089738A3 (en) Proteomimetic compounds and methods
WO2003082208A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
AUPS323902A0 (en) Compositions and methods for treating gynaecological disorders
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
WO2004087073A3 (en) Treatment of demyelinating conditions
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof
WO2002083622A3 (en) Novel aminophenyl ketone derivatives
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
AU2002332598A1 (en) Compositions and methods for generating antigen-binding units
AU2002346882A1 (en) Methods for the treatment of osteoarthritis and compositions thereof
AU2002249983A1 (en) Compositions and methods for diagnosis of neuropsychiatric disorders
WO2005044244A3 (en) Use of mrp4-inhibitors for the treatment and/or prophylaxis of cardiovascular diseases
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 527396

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003/06071

Country of ref document: ZA

Ref document number: 200306071

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002252097

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2438238

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007413

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002721152

Country of ref document: EP

Ref document number: 2002567986

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002721152

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: PI0207528

Country of ref document: BR